MediWound (NASDAQ:MDWD) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

Shares of MediWound Ltd. (NASDAQ:MDWD) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $15.48 and traded as low as $13.03. MediWound shares last traded at $13.29, with a volume of 86,155 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MDWD shares. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target (down from $32.00) on shares of MediWound in a report on Friday, August 14th. Wall Street Zen cut shares of MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of MediWound in a report on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MediWound has an average rating of “Hold” and a consensus target price of $33.00.

MediWound Stock Performance

The business has a 50-day simple moving average of $14.00 and a 200 day simple moving average of $15.48. The firm has a market cap of $170.80 million, a P/E ratio of -7.38 and a beta of 0.14.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.The business had revenue of $3.09 million during the quarter, compared to the consensus estimate of $2.59 million. On average, research analysts expect that MediWound Ltd. will post -2.31 EPS for the current year.

Insider Buying and Selling

In related news, COO Shmuel Hess sold 3,958 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $12.92, for a total value of $51,137.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Rhumbline Advisers increased its position in shares of MediWound by 4.4% during the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 481 shares during the period. Russell Investments Group Ltd. increased its position in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares during the period. Marshall Wace LLP bought a new position in MediWound in the second quarter worth about $317,000. Finally, The Manufacturers Life Insurance Company raised its stake in MediWound by 104.4% in the second quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 13,312 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.